BioCryst, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded BioCryst a $12.2 million contract to develop and manufacture Ebola treatment BCX4430. The base contract will support improvements to the manufacturing process and scale-up production of BCX4430 in U.S. facilities. BARDA has the option to extend the contract through August 2017 and provide an additional $22.9 million.

The RNA-dependent RNA polymerase inhibitor is in Phase I testing with funding from NIH’s National Institute of Allergy and Infectious Disease (NIAID). Results from a Phase I trial of intramuscular BCX4430 are expected in 3Q15. ...